Table 4 Some of the significantly enriched pathways that are related to COVID-19 essential proteins (E)

hsa05142:Chagas disease (American trypanosomiasis)

20

2.47E−18

[27]

hsa05323:Rheumatoid arthritis

17

1.79E−15

[27]

hsa05144:Malaria

14

4.85E−15

[27]

hsa05321:Inflammatory bowel disease (IBD)

15

7.61E−15

[27]

hsa05140:Leishmaniasis

14

8.80E−13

[27]

hsa05152:Tuberculosis

19

9.13E−13

[27]

hsa04620:Toll-like receptor signaling pathway

15

1.15E−11

[28]

hsa05146:Amoebiasis

14

1.75E−10

[27]

hsa05145:Toxoplasmosis

14

2.81E−10

[27]

hsa05134:Legionellosis

10

8.56E−09

[29]

hsa05133:Pertussis

10

1.66E−07

[27]

hsa04621:NOD-like receptor signaling pathway

9

2.12E−07

[30]

hsa05168:Herpes simplex infection

20

1.31E−13

[29]

hsa04940:Type I diabetes mellitus

12

8.30E−13

[27]

hsa05332:Graft-versus-host disease

11

1.89E−12

hsa05330:Allograft rejection

10

2.35E−10

[27]

hsa05320:Autoimmune thyroid disease

7

2.72E−05

[27]

hsa04931:Insulin resistance

10

3.80E−06

hsa04920:Adipocytokine signaling pathway

8

1.47E−05

[28]

hsa05221:Acute myeloid leukemia

6

4.50E−04